Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-613 and Docetaxel in Advanced NSCLC
NCT03370159Phase 2Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jun 2018
- Primary completion
- Mar 2019
- Countries
- 1
01
Overview
A Phase 2 trial of devimistat in non-small cell lung cancer (NSCLC), sponsored by Wake Forest University Health Sciences. Planned start Jun 2018; status: withdrawn.
02
Drugs
devimistat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03370159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03370159.